Ionis Pharmaceuticals, Inc. engages in the development and commercialization of human therapeutic drugs using antisense technology. It operates through the Ionis Core and Akcea Therapeutics segments.

Morgan Stanley lowered the firm’s price target on Ionis Pharmaceuticals (IONS) to $52 from $55 and keeps an Equal Weight rating on the shares.

Ionis Pharmaceuticals IONS shares rallied 8.9% in the last trading session to close at $27.77. This move can be attributable to notable volume with a higher number of shares being traded than in a ...

In a report released today, Michael Ulz from Morgan Stanley maintained a Hold rating on Ionis Pharmaceuticals (IONS – Research Report), with a ...

Ionis Pharmaceuticals (NASDAQ:IONS – Get Free Report)‘s stock had its “buy” rating reaffirmed by equities researchers at ...

H.C. Wainwright initiated coverage of Ionis Pharmaceuticals (IONS) with a Buy rating and $45 price target Ionis is a commercial-stage biotech ...

Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $55.0, with a high ...

Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today it will host a webinar on Monday, April 14th at 11:00 a.m. ET ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

A new drug in clinical trials is showing promise in lowering a key genetic risk factor for heart attacks and ...

Learn more about whether Ionis Pharmaceuticals, Inc. or Moderna, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Research analysts at Redburn Atlantic began coverage on shares of Ionis Pharmaceuticals (NASDAQ:IONS – Get Free Report) in a ...